Kenichi Fujise

US Patent:

8415384, Apr 9, 2013

Filed:

Jun 12, 2009

Appl. No.:

12/997485

Inventors:

Kenichi Fujise - Galveston TX, US
Barry F. Uretsky - Fort Smith AR, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX

International Classification:

A61K 31/44
A61K 31/675
A61K 31/135
A61P 9/10

US Classification:

514352, 514 94, 514651, 514824

Abstract:

Embodiments of the invention are directed to methods of treating reperfusion or resuscitation injury in an individual in need of such treatment, comprising the step of administering to the individual who has had, having, or is at immediate risk of having an ischemic event an amount of a composition comprising a protein kinase A (PKA) activator and a β-adrenergic receptor antagonist sufficient to reduce reperfusion injury to an ischemic tissue.

US Patent:

20040242470, Dec 2, 2004

Filed:

May 30, 2003

Appl. No.:

10/448664

Inventors:

Kenichi Fujise - Houston TX, US
Zakar Mnjoyan - Houston TX, US

International Classification:

A61K038/17
C07K014/705

US Classification:

514/012000, 530/350000

Abstract:

Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of preventing or treating restenosis by administering the new compositions are disclosed. Also disclosed are methods for treating patients undergoing angioplasty procedures, patients with atherosclerosis, and patients with other proliferative disorders, in order to suppress the growth of vascular smooth muscle cells or other cells that play a role in the particular proliferative disorder or condition. A method of screening mRNAs and identifying genes encoding PARISs is also disclosed.

US Patent:

20070054853, Mar 8, 2007

Filed:

Aug 3, 2006

Appl. No.:

11/462106

Inventors:

Kenichi Fujise - Houston TX, US
Zakar Mnjoyan - Houston TX, US

Assignee:

BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

A61K 38/17

US Classification:

514012000

Abstract:

Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of preventing or treating restenosis by administering the new compositions are disclosed. Also disclosed are methods for treating patients undergoing angioplasty procedures, patients with atherosclerosis, and patients with other proliferative disorders, in order to suppress the growth of vascular smooth muscle cells or other cells that play a role in the particular proliferative disorder or condition. A method of screening mRNAs and identifying genes encoding PARISs is also disclosed.

US Patent:

20090022776, Jan 22, 2009

Filed:

Aug 21, 2008

Appl. No.:

12/195735

Inventors:

Kenichi FUJISE - Houston TX, US
Zakar H. MNJOYAN - Houston TX, US

International Classification:

A61K 9/00
C12N 5/02
C07K 14/435
A61P 35/04
C12Q 1/68
A61K 38/16

US Classification:

424423, 435375, 530320, 514 12, 435 6

Abstract:

Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of preventing or treating restenosis by administering the new compositions are disclosed. Also disclosed are methods for treating patients undergoing angioplasty procedures, patients with atherosclerosis, and patients with other proliferative disorders, in order to suppress the growth of vascular smooth muscle cells or other cells that play a role in the particular proliferative disorder or condition. A method of screening mRNAs and identifying genes encoding PARISs is also disclosed.

US Patent:

20110217293, Sep 8, 2011

Filed:

Jan 28, 2011

Appl. No.:

12/931310

Inventors:

Kenichi Fujise - Galveston TX, US
Nongporn Towatana - Hat Yai, TH
Wilawan Mahabusarakam - Songkhia, TH

International Classification:

A61K 39/395
A61K 31/352
A61K 31/40
A61K 31/4418
A61K 31/405
A61K 31/47
A61K 31/505
A61K 31/616
A61K 31/4365
A61K 31/519
A61P 9/10
A61P 3/06
A61P 7/02

US Classification:

4241331, 514456, 514423, 514277, 514415, 514311, 514275, 514161, 514301, 5142621

Abstract:

Provided herein are methods of treating postangiplasty, in-stent restenosis or atherosclerosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone with or with a effective dose of one or more of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent. Also provided are pharmaceutical compositions comprising a morelloflavone or pharmaceutical combinations comprising a morelloflavone and one of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent.